您当前所在的位置:首页 > 产品中心 > 产品信息
Phenacemide_分子结构_CAS_63-98-9)
点击图片或这里关闭

Phenacemide

产品号 DB01121 公司名称 DrugBank
CAS号 63-98-9 公司网站 http://www.ualberta.ca/
分子式 C9H10N2O2 电 话 (780) 492-3111
分子量 178.1879 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 992

产品价格信息

请登录

产品别名

标题
Phenacemide
IUPAC标准名
(2-phenylacetyl)urea
IUPAC传统名
phenacemide
商标名
Neophedan
Fenacemide
Fenacemid
Phenurone
Felurea
Acetylureum
Epheron
Epiclase
Fenacetil-Karbamide
Fenilep
Fenural
Neophenal
Phenacereum
Phenicarb
Phenutal
Carbanmide
Cetylureum
Comitiadone
Eferon
Efron
Fenacetamide
Fenised
Fenostenyl
Fenurea
Fenurone
Fenylacetylmocovina
Fenytan
Phacetur
Phenacalum
Phenacetur
Phenarone
Phenuron
Phenyrit
Phetylureum
别名
PA
Phenacetylcarbamide
Phenylacetylurea
Carbamide phenylacetate
Phenacetylurea
Phenylacetyluree

产品登记号

PubChem CID 4753
PubChem SID 46508400
CAS号 63-98-9

产品性质

疏水性(logP) 0.8
溶解度 10.2 g/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Indication Used to control certain seizures in the treatment of epilepsy.
Pharmacology Phenacemide is a ureal anticonvulsant indicated for control of severe epilepsy, particularly mixed forms of complex partial (psychomotor or temporal lobe) seizures, refractory to other anticonvulsants. Phenacemide elevates the threshold for minimal electroshock convulsions and abolishes the tonic phase of maximal electroshock seizures. It also prevents or modifies seizures induced by pentylenetetrazol or other convulsants.
Toxicity Oral, mouse: LD50 = 987 mg/kg; Oral, rabbit: LD50 = 2500 mg/kg; Oral, rat: LD50 = 1600 mg/kg
Affected Organisms
Humans and other mammals
Biotransformation Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation.
Absorption Almost completely absorbed.
Half Life 22-25 hours.
References
Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. [Pubmed]
Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. [Pubmed]
External Links
Wikipedia

参考文献

  • Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. Pubmed
  • Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. Pubmed